Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Gland Pharma Limited
GLAND | NSE
1,713.50
INR-81.90
-4.56%
GLAND | NSE
Loading StockChartView...
About Gland Pharma Limited
Sector
Healthcare
Industry
Drug Manufacturers-General
Earnings date
31/03/2024
As of date
24/04/2026
Close
1,713.50
Open
1,791.50
High
1,798.10
Low
1,702.90
Gland Pharma Limited a generic injectable-focused company engages in the development manufacture sale and distribution of pharmaceuticals. The company's primary molecules include heparin sodium enoxaparin sodium rocuronium bromide and daptomycin injections as well as others. It offers its products for various therapeutic categories such as anti-infectives anesthetics anti-coagulants and their antidotes anti-malarial cardiology gastro-intestinal hormones and related drugs fertility supplements Gnrh agonists and antagonists as well as anti-neoplastic gynecological neurological and central nervous system respiratory blood related ophthalmological and otological pain/analgesics vitamins/minerals/nutrients and others. The company also provides contract development services. It sells its products primarily under a business-to-business model in the United States Europe Canada Australia India and internationally. The company was incorporated in 1978 and is based in Hyderabad India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.
View LessGLAND | NSE
Risk
27.4
Sharpe
0.60
Luna's Score
61/100
Recommendation
Hold
Luna says (GLAND | NSE)
What's Working
Low 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
33.4%1 month
27.4%3 months
31.6%6 months
26.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
36.79
Fwd. PE
51.28
Price to book
3.15
Debt to equity
0.04
Debt to assets
0.03
Ent. to EBITDA
17.27
Ent. to rev.
4.59
PEG
-
Other Fundamentals
EBITDA
13.26B
MarketCap
275.84B
MarketCap(USD)
2.85B
Div. yield
1.20
Op. margin
12.30
Erngs. growth
-25.90
Rev. growth
16.00
Ret. on equity
9.26
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
138.70
Range1M
180.00
Range3M
411.30
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.71
Price X volume
276.41M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 17.27 | 25.64 | Cheaper |
| Ent. to Revenue | 4.59 | 6.59 | Cheaper |
| PE Ratio | 36.79 | 41.48 | Par |
| Price to Book | 3.15 | 10.46 | Cheaper |
| Dividend Yield | 1.20 | 0.96 | Leader |
| Std. Deviation (3M) | 31.61 | 41.14 | Lower Risk |
| Debt to Equity | 0.04 | 0.14 | Cheaper |
| Debt to Assets | 0.03 | 0.08 | Cheaper |
| Market Cap | 275.84B | 186.70B | Market Leader |
